Oral Cancer Clinical Trial
Official title:
Web-based Education on Oral Cancer for Primary Care Physicians in Ohio
Verified date | December 2012 |
Source | Creighton University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Objective:
The experimental design is a one-site, randomized experimental web-based educational
feasibility intervention trial, with approximately 50% primary care physicians (PCPs) in the
intervention group and approximately 50% PCPs on the control group, giving a total of 159
participants. All 159 participants have willingly provided their e-mail addresses, as part
of a survey they previously completed entitled, "Survey of Health Professionals on Oral
Cancer in Ohio- Intervention to Prevent Delayed Diagnosis of Oral Cancer."
Status | Completed |
Enrollment | 10 |
Est. completion date | September 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The PCP's who participated in Specific Aim #2 (Survey of Healthcare Professionals on Oral Cancer in Ohio ) of the NIH K23 grant proposal, "Intervention to Prevent Delayed Diagnosis of Oral Cancer", will be eligible to participate in this Web-Based Education on Oral Cancer. - Possessing the ability to give voluntary consent to participate. Participating in the web-based educational intervention is am implication of consent. - All participants are expected to be relatively healthy. Exclusion Criteria: • Unable to have access to the internet to be able to participate in the web-based education. |
Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
Country | Name | City | State |
---|---|---|---|
United States | Creighton University School of Dentistry | Omaha | Nebraska |
Lead Sponsor | Collaborator |
---|---|
Creighton University | National Institute of Dental and Craniofacial Research (NIDCR) |
United States,
Canto MT, Devesa SS. Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. Oral Oncol. 2002 Sep;38(6):610-7. — View Citation
Canto MT, Drury TF, Horowitz AM. Use of skin and oral cancer examinations in the United States, 1998. Prev Med. 2003 Sep;37(3):278-82. — View Citation
Goodman HS, Yellowitz JA, Horowitz AM. Oral cancer prevention. The role of family practitioners. Arch Fam Med. 1995 Jul;4(7):628-36. Review. — View Citation
Horowitz AM, Moon HS, Goodman HS, Yellowitz JA. Maryland adults' knowledge of oral cancer and having oral cancer examinations. J Public Health Dent. 1998 Fall;58(4):281-7. — View Citation
Horowitz AM, Nourjah PA. Factors associated with having oral cancer examinations among US adults 40 years of age or older. J Public Health Dent. 1996 Fall;56(6):331-5. — View Citation
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47. Erratum in: CA Cancer J Clin 2002 Mar-Apr;52(2):119. CA Cancer J Clin 2002 May-Jun;52(3):181-2. — View Citation
Mashberg A, Garfinkel L. Early diagnosis of oral cancer: the erythroplastic lesion in high risk sites. CA Cancer J Clin. 1978 Sep-Oct;28(5):297-303. — View Citation
Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc. 2001 Nov;132 Suppl:7S-11S. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Index of knowledge of diagnostic procedure for oral cancer | The list of participants will be sent an initial email inviting them to view the module and complete a pre test (control group) or a post test (intervention group). Reminder emails will be sent every 2 months for up to 6 months following the initial email. It is expected that at least a 15% higher proportion of Intervention group PCPs will attain the high score category for each of this index, as compared to the Control group PCPs. | An average of 8 months from the time of the initial email sent on 7/21/11. | No |
Secondary | To determine if a change in Stage of Diagnosis of Oral Cancer occurred for the particular year of Web-based Educational Intervention. | Three years post-web-based education intervention data will be requested from Ohio Cancer Incidence Surveillance System (OCISS). OCISS's cleaning and processing of the data takes approximately three years. Comparison using Chi-square will be carried out pre- and post- intervention years. | 3 years | No |
Secondary | Index of knowledge of risk factors for oral cancer. | The list of participants will be sent an initial email inviting them to view the module and complete a pre test (control group) or a post test (intervention group). Reminder emails will be sent every 2 months for up to 6 months following the initial email. It is expected that at least a 15% higher proportion of Intervention group PCP's will attain the high score category for this index, as compared to the Control group PCP's. | An average of 8 months from the time of the initial email sent on 7/21/11. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT00933387 -
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Recruiting |
NCT03684707 -
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
|
Phase 4 | |
Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
Recruiting |
NCT04372914 -
Prevention of Oral DNA Damage by Black Raspberries
|
N/A | |
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Recruiting |
NCT03686020 -
Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)
|
||
Not yet recruiting |
NCT06060288 -
Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening
|
||
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01418118 -
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
|
Phase 4 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Completed |
NCT04614896 -
Use of Ultrasound for Measuring Size of Oral Tongue Cancers
|
N/A | |
Recruiting |
NCT03685409 -
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
|
Phase 3 | |
Completed |
NCT00402779 -
Erlotinib Prevention of Oral Cancer (EPOC)
|
Phase 3 | |
Recruiting |
NCT05153733 -
Improved Implant for Reconstruction Purposes After Mandibular Resection
|
N/A |